474 related articles for article (PubMed ID: 36293225)
1. The Implications of Noncoding RNAs in the Evolution and Progression of Nonalcoholic Fatty Liver Disease (NAFLD)-Related HCC.
Rusu I; Pirlog R; Chiroi P; Nutu A; Puia VR; Fetti AC; Rusu DR; Berindan-Neagoe I; Al Hajjar N
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293225
[TBL] [Abstract][Full Text] [Related]
2. Noncoding RNAs as additional mediators of epigenetic regulation in nonalcoholic fatty liver disease.
Zaiou M
World J Gastroenterol; 2022 Sep; 28(35):5111-5128. PubMed ID: 36188722
[TBL] [Abstract][Full Text] [Related]
3. Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: dysregulation and implications for early detection, diagnosis and therapy.
Hou W; Bonkovsky HL
World J Gastroenterol; 2013 Nov; 19(44):7836-45. PubMed ID: 24307777
[TBL] [Abstract][Full Text] [Related]
4. Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers.
Khalifa O; Errafii K; Al-Akl NS; Arredouani A
Dis Markers; 2020; 2020():8822859. PubMed ID: 33133304
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNAs as modulators and therapeutic targets in non-alcoholic fatty liver disease (NAFLD).
Tao Q; Xie J; Wu Y; Jin Y
Gastroenterol Hepatol; 2024 May; 47(5):506-516. PubMed ID: 37806343
[TBL] [Abstract][Full Text] [Related]
6. The impact and role of identified long noncoding RNAs in nonalcoholic fatty liver disease: A narrative review.
Shi N; Sun K; Tang H; Mao J
J Clin Lab Anal; 2023 Jun; 37(11-12):e24943. PubMed ID: 37435630
[TBL] [Abstract][Full Text] [Related]
7. Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications.
Wong CM; Tsang FH; Ng IO
Nat Rev Gastroenterol Hepatol; 2018 Mar; 15(3):137-151. PubMed ID: 29317776
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma.
Gori M; Arciello M; Balsano C
Biomed Res Int; 2014; 2014():741465. PubMed ID: 24745023
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA GAS5 contributes to the progression of nonalcoholic fatty liver disease by targeting the microRNA-29a-3p/NOTCH2 axis.
Cui J; Wang Y; Xue H
Bioengineered; 2022 Apr; 13(4):8370-8381. PubMed ID: 35322757
[TBL] [Abstract][Full Text] [Related]
10. Role of MicroRNAs in the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
Zhang C; Wang P; Li Y; Huang C; Ni W; Chen Y; Shi J; Chen G; Hu X; Ye M; Duan S; Wang K
Anat Rec (Hoboken); 2019 Feb; 302(2):193-200. PubMed ID: 30312023
[TBL] [Abstract][Full Text] [Related]
11. Exploring the Regulatory Role of ncRNA in NAFLD: A Particular Focus on PPARs.
Mukherjee AG; Wanjari UR; Gopalakrishnan AV; Katturajan R; Kannampuzha S; Murali R; Namachivayam A; Ganesan R; Renu K; Dey A; Vellingiri B; Prince SE
Cells; 2022 Dec; 11(24):. PubMed ID: 36552725
[TBL] [Abstract][Full Text] [Related]
12. Non-coding RNA-associated competitive endogenous RNA regulatory networks: Novel diagnostic and therapeutic opportunities for hepatocellular carcinoma.
Khashkhashi Moghadam S; Bakhshinejad B; Khalafizadeh A; Mahmud Hussen B; Babashah S
J Cell Mol Med; 2022 Jan; 26(2):287-305. PubMed ID: 34907642
[TBL] [Abstract][Full Text] [Related]
13. The interplay between noncoding RNAs and drug resistance in hepatocellular carcinoma: the big impact of little things.
Fang Y; Zhang X; Huang H; Zeng Z
J Transl Med; 2023 Jun; 21(1):369. PubMed ID: 37286982
[TBL] [Abstract][Full Text] [Related]
14. Noncoding RNAs in liver cancer stem cells: The big impact of little things.
Lv H; Lv G; Han Q; Yang W; Wang H
Cancer Lett; 2018 Apr; 418():51-63. PubMed ID: 29307614
[TBL] [Abstract][Full Text] [Related]
15. Decoding hepatocarcinogenesis from a noncoding RNAs perspective.
El-Aziz MKA; Dawoud A; Kiriacos CJ; Fahmy SA; Hamdy NM; Youness RA
J Cell Physiol; 2023 Sep; 238(9):1982-2009. PubMed ID: 37450612
[TBL] [Abstract][Full Text] [Related]
16. A micro-RNA expression signature for human NAFLD progression.
Guo Y; Xiong Y; Sheng Q; Zhao S; Wattacheril J; Flynn CR
J Gastroenterol; 2016 Oct; 51(10):1022-30. PubMed ID: 26874844
[TBL] [Abstract][Full Text] [Related]
17. Noncoding RNA as therapeutic targets for hepatocellular carcinoma.
George J; Patel T
Semin Liver Dis; 2015 Feb; 35(1):63-74. PubMed ID: 25632936
[TBL] [Abstract][Full Text] [Related]
18. MiRNA-192 [corrected] and miRNA-204 Directly Suppress lncRNA HOTTIP and Interrupt GLS1-Mediated Glutaminolysis in Hepatocellular Carcinoma.
Ge Y; Yan X; Jin Y; Yang X; Yu X; Zhou L; Han S; Yuan Q; Yang M
PLoS Genet; 2015 Dec; 11(12):e1005726. PubMed ID: 26710269
[TBL] [Abstract][Full Text] [Related]
19. Transcriptomic Analysis of mRNA-lncRNA-miRNA Interactions in Hepatocellular Carcinoma.
Tang X; Feng D; Li M; Zhou J; Li X; Zhao D; Hao B; Li D; Ding K
Sci Rep; 2019 Nov; 9(1):16096. PubMed ID: 31695090
[TBL] [Abstract][Full Text] [Related]
20. Long noncoding RNAs in nonalcoholic fatty liver disease and liver fibrosis: state-of-the-art and perspectives in diagnosis and treatment.
De Vincentis A; Rahmani Z; Muley M; Vespasiani-Gentilucci U; Ruggiero S; Zamani P; Jamialahmadi T; Sahebkar A
Drug Discov Today; 2020 Jul; 25(7):1277-1286. PubMed ID: 32439605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
